Log in

NASDAQ:EOLSEvolus Stock Price, Forecast & News

+0.41 (+10.07 %)
(As of 05/25/2020 03:28 PM ET)
Today's Range
Now: $4.48
50-Day Range
MA: $4.09
52-Week Range
Now: $4.48
Volume13.11 million shs
Average Volume1.15 million shs
Market Capitalization$151.11 million
P/E RatioN/A
Dividend YieldN/A
Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was founded in 2012 and is headquartered in Newport Beach, California. Evolus, Inc. is a subsidiary of ALPHAEON Corporation.
Read More
Evolus logo

Beat the Market (BTM) Rank

Analyst Opinion: 4.3Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.75 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:EOLS



Sales & Book Value

Annual Sales$34.92 million
Book Value$2.38 per share


Net Income$-90,030,000.00
Net Margins-217.51%


Market Cap$151.11 million
Next Earnings Date8/10/2020 (Estimated)

Receive EOLS News and Ratings via Email

Sign-up to receive the latest news and ratings for EOLS and its competitors with MarketBeat's FREE daily newsletter.

Evolus (NASDAQ:EOLS) Frequently Asked Questions

How has Evolus' stock been impacted by COVID-19 (Coronavirus)?

Evolus' stock was trading at $5.91 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, EOLS stock has decreased by 24.2% and is now trading at $4.48. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Evolus?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Evolus in the last year. There are currently 1 sell rating, 1 hold rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Evolus.

When is Evolus' next earnings date?

Evolus is scheduled to release its next quarterly earnings announcement on Monday, August 10th 2020. View our earnings forecast for Evolus.

How were Evolus' earnings last quarter?

Evolus Inc (NASDAQ:EOLS) posted its quarterly earnings data on Monday, May, 11th. The company reported ($0.75) earnings per share for the quarter, missing the consensus estimate of ($0.72) by $0.03. The firm had revenue of $10.50 million for the quarter, compared to the consensus estimate of $16.91 million. Evolus had a negative net margin of 217.51% and a negative return on equity of 197.30%. View Evolus' earnings history.

What price target have analysts set for EOLS?

8 Wall Street analysts have issued 1-year target prices for Evolus' shares. Their forecasts range from $4.00 to $30.00. On average, they anticipate Evolus' stock price to reach $14.25 in the next year. This suggests a possible upside of 218.1% from the stock's current price. View analysts' price targets for Evolus.

Has Evolus been receiving favorable news coverage?

Media stories about EOLS stock have been trending somewhat positive on Monday, according to InfoTrie Sentiment Analysis. InfoTrie identifies negative and positive media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Evolus earned a daily sentiment score of 1.5 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View the latest news aboutEvolus.

Are investors shorting Evolus?

Evolus saw a decrease in short interest in May. As of May 15th, there was short interest totaling 3,790,000 shares, a decrease of 37.8% from the April 30th total of 6,090,000 shares. Based on an average trading volume of 629,000 shares, the days-to-cover ratio is presently 6.0 days. Approximately 17.3% of the shares of the company are sold short. View Evolus' Current Options Chain.

Who are some of Evolus' key competitors?

What other stocks do shareholders of Evolus own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Evolus investors own include Celadon Group (CGI), Advanced Micro Devices (AMD), Revance Therapeutics (RVNC), Camtek (CAMT), Plug Power (PLUG), Micron Technology (MU), Canopy Growth (CGC), Tandem Diabetes Care (TNDM), Calithera Biosciences (CALA) and JD.Com (JD).

Who are Evolus' key executives?

Evolus' management team includes the following people:
  • Mr. David Moatazedi, Pres, CEO & Director (Age 41)
  • Ms. Lauren P. Silvernail, CFO & Exec. VP of Corp. Devel. (Age 60)
  • Mr. Michael Mazen Jafar, Chief Marketing Officer (Age 38)
  • Mr. Alejandro Sabad, VP of Operations
  • Mr. Ashwin K. Agarwal, VP of Fin., Investor Relations & Treasury

When did Evolus IPO?

(EOLS) raised $65 million in an IPO on Thursday, February 8th 2018. The company issued 5,000,000 shares at $12.00-$14.00 per share. Cantor and Mizuho Securities acted as the underwriters for the IPO and SunTrust Robinson Humphrey and JMP Securities were co-managers.

What is Evolus' stock symbol?

Evolus trades on the NASDAQ under the ticker symbol "EOLS."

Who are Evolus' major shareholders?

Evolus' stock is owned by many different institutional and retail investors. Top institutional investors include Tang Capital Management LLC (9.77%), BlackRock Inc. (4.88%), MFN Partners Management LP (4.21%), Stonepine Capital Management LLC (2.44%), Sphera Funds Management LTD. (1.63%) and State Street Corp (1.06%). Company insiders that own Evolus stock include Bosun Hau, Corp Alphaeon, David N Gill, Kristine Romine, Lauren P Silvernail, Michael M Jafar, Rui Avelar, Simone Blank and Vikram Malik. View institutional ownership trends for Evolus.

Which institutional investors are selling Evolus stock?

EOLS stock was sold by a variety of institutional investors in the last quarter, including Wells Fargo & Company MN, BlackRock Inc., UBS Group AG, Global Retirement Partners LLC, and Janney Montgomery Scott LLC. Company insiders that have sold Evolus company stock in the last year include Lauren P Silvernail, and Rui Avelar. View insider buying and selling activity for Evolus.

Which institutional investors are buying Evolus stock?

EOLS stock was purchased by a variety of institutional investors in the last quarter, including MFN Partners Management LP, Tang Capital Management LLC, Stonepine Capital Management LLC, Sphera Funds Management LTD., Alyeska Investment Group L.P., Morgan Stanley, State Street Corp, and Citigroup Inc.. Company insiders that have bought Evolus stock in the last two years include Bosun Hau, David N Gill, Kristine Romine, Michael M Jafar, Simone Blank, and Vikram Malik. View insider buying and selling activity for Evolus.

How do I buy shares of Evolus?

Shares of EOLS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Evolus' stock price today?

One share of EOLS stock can currently be purchased for approximately $4.48.

How big of a company is Evolus?

Evolus has a market capitalization of $151.11 million and generates $34.92 million in revenue each year. The company earns $-90,030,000.00 in net income (profit) each year or ($3.19) on an earnings per share basis. Evolus employs 70 workers across the globe.

What is Evolus' official website?

The official website for Evolus is www.evolus.com.

How can I contact Evolus?

Evolus' mailing address is 520 Newport Center Dr. Suite 1200, Newport Beach CA, 92660. The company can be reached via phone at 949-284-4555 or via email at [email protected]

This page was last updated on 5/25/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.